Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abatacept in the treatment of rheumatoid arthritis.
Buch MH, Vital EM, Emery P. Buch MH, et al. Among authors: vital em. Arthritis Res Ther. 2008;10 Suppl 1(Suppl 1):S5. doi: 10.1186/ar2416. Epub 2008 Oct 15. Arthritis Res Ther. 2008. PMID: 19007425 Free PMC article. Review.
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Rönnblom L, Versnel MA, Vital EM. Rodríguez-Carrio J, et al. Among authors: vital em. Ann Rheum Dis. 2023 Jun;82(6):754-762. doi: 10.1136/ard-2022-223628. Epub 2023 Mar 1. Ann Rheum Dis. 2023. PMID: 36858821 Free article.
Musculoskeletal manifestations of systemic lupus erythematosus.
Shumilova A, Vital EM. Shumilova A, et al. Among authors: vital em. Best Pract Res Clin Rheumatol. 2023 Dec;37(4):101859. doi: 10.1016/j.berh.2023.101859. Epub 2023 Aug 22. Best Pract Res Clin Rheumatol. 2023. PMID: 37620235 Review.
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Burska A, Rodríguez-Carrio J, Biesen R, Dik WA, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Conaghan PG, Versnel M, Vital E. Burska A, et al. RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
Co-stimulatory blockade as therapy for rheumatoid arthritis.
Mackie SL, Vital EM, Ponchel F, Emery P. Mackie SL, et al. Among authors: vital em. Curr Rheumatol Rep. 2005 Oct;7(5):400-6. doi: 10.1007/s11926-005-0029-4. Curr Rheumatol Rep. 2005. PMID: 16174492 Review.
Abatacept.
Vital EM, Emery P. Vital EM, et al. Drugs Today (Barc). 2006 Feb;42(2):87-93. doi: 10.1358/dot.2006.42.2.957359. Drugs Today (Barc). 2006. PMID: 16541185
129 results